Related Experiment Video
Updated: Jul 7, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Circulating Plasma Circular RNAs hsa_circ_0001785 and hsa_circ_0079876 as Promising Noninvasive Diagnostic Biomarkers
Amirhossein Sangi Nasab Lahijan1, Sepideh Abdollahi1, Seyed Rohollah Miri2
1Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
The Breast Journal
|July 6, 2026
Summary
Plasma levels of two circular RNAs (circRNAs), hsa_circ_0001785 and hsa_circ_0079876, are significantly elevated in breast cancer (BC) patients. hsa_circ_0079876 shows high potential for noninvasive BC detection.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Breast cancer (BC) poses a significant health risk to women, underscoring the need for early diagnosis.
- Mammography, while standard, has limitations; circular RNAs (circRNAs) are emerging as stable, promising biomarkers in body fluids.
- circRNAs are noncoding RNAs with a unique covalently closed loop structure, offering stability for diagnostic applications.
Purpose of the Study:
- To investigate plasma levels of hsa_circ_0001785 and hsa_circ_0079876 in BC patients versus healthy controls.
- To evaluate the potential of these circRNAs as noninvasive biomarkers for early breast cancer detection.
- To compare the diagnostic performance of individual circRNAs and their combination.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to measure plasma circRNA levels.
- RNA was extracted from plasma samples of 81 BC patients and 48 healthy controls.
- Receiver operating characteristic (ROC) curve analysis assessed diagnostic value.
Main Results:
- Both hsa_circ_0001785 and hsa_circ_0079876 showed significantly higher expression in BC patients (p < 0.001).
- hsa_circ_0079876 demonstrated high diagnostic accuracy with an Area Under the Curve (AUC) of 0.98 (93% sensitivity, 92% specificity).
- The combination of both circRNAs also achieved an AUC of 0.98, indicating strong diagnostic potential.
Conclusions:
- Plasma hsa_circ_0001785 and hsa_circ_0079876 levels are significantly elevated in breast cancer patients.
- hsa_circ_0079876 exhibits superior sensitivity and specificity compared to hsa_circ_0001785 for BC detection.
- hsa_circ_0079876 is a promising biomarker for noninvasive breast cancer diagnosis in a case-control setting.
